Welcome to our dedicated page for Relmada Therapeutics news (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics stock.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company whose news flow centers on the development of NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for central nervous system conditions. Company press releases frequently highlight clinical data readouts, regulatory interactions, and financing events that shape the outlook for its pipeline.
Recent news has focused on NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel in development for NMIBC. Relmada has reported 6‑month and 9‑month follow-up data from an open-label Phase 2 study, including complete response rates at various time points, safety findings, and outcomes such as absence of progression to muscle-invasive disease and lack of radical cystectomy among reported patients. Updates also describe treatment-related adverse events and their severity profile.
Another key theme in RLMD news is FDA regulatory feedback. The company has announced written guidance from the FDA supporting two potential registrational study paths for NDV-01: a single-arm trial in high-grade, 2nd-line BCG-unresponsive NMIBC with carcinoma in situ and a randomized-to-observation trial in intermediate-risk NMIBC in the adjuvant setting. These items are often accompanied by timelines for anticipated Phase 3 trial initiation and expectations around a 505(b)(2) regulatory pathway.
Relmada’s news feed also covers corporate and financial updates, including quarterly financial results, underwritten equity offerings, Nasdaq listing compliance notices, and additions to its clinical advisory board. For sepranolone, press releases describe its GABAA-modulating mechanism and planned Phase 2 development in Prader-Willi syndrome and other compulsivity-related disorders. Investors monitoring RLMD news can use this page to follow clinical milestones, regulatory developments, capital-raising activities, and other disclosures that the company furnishes through GlobeNewswire and SEC-related announcements.
Relmada Therapeutics (NASDAQ: RLMD) reported its Q2 2024 financial results and provided a business update. Key highlights include:
- Anticipated outcome of Reliance II interim analysis by YE 2024
- Expected completion of Phase 3 Reliance II study enrollment by YE 2024
- Preparations for Phase 1 study of REL-P11 for metabolic disorders by YE 2024
- Cash position of $70.4 million, providing runway through key milestones into 2025
Financial results for Q2 2024:
- R&D expense: $10.7 million, down from $13.7 million in Q2 2023
- G&A expense: $8.1 million, down from $12.3 million in Q2 2023
- Net loss: $17.8 million ($0.59 per share), compared to $25.3 million ($0.84 per share) in Q2 2023
Relmada Therapeutics (Nasdaq: RLMD), a late-stage biotechnology company focusing on central nervous system (CNS) diseases, has announced its plans to host a conference call and webcast on August 7, 2024, at 4:30 PM ET. The event will discuss recent business progress and financial results for the second quarter ended June 30, 2024.
Participants can join the call using US dial-in 1-800-717-1738 or international dial-in 1-646-307-1865, with conference code 39584. Alternatively, they can use the 'Call me™' technology for instant telephone access. A webcast replay will be available in the Investors section of Relmada's website after the event.
Relmada Therapeutics announced the publication of Phase 3 clinical data for REL-1017 (esmethadone) from the Reliance I Study in The Journal of Clinical Psychiatry. The study focused on patients with Major Depressive Disorder (MDD) who had an inadequate response to standard antidepressants. The results confirmed the efficacy, safety, and tolerability of esmethadone, aligning with previous Phase 2 findings. The side-effect profile was favorable compared to current FDA-approved treatments for MDD, highlighting esmethadone's potential as an adjunctive therapy.
Relmada Therapeutics announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, set for June 12, 2024. CEO Sergio Traversa will engage in a fireside chat at 11:20am ET. The company will also conduct one-on-one investor meetings. The event will be webcast live and accessible through the Relmada website, with a replay available for 90 days. This highlights Relmada's strategic engagement with investors and stakeholders in the CNS disease treatment sector.
Relmada Therapeutics, a late-stage biotechnology company focusing on CNS diseases, announced its participation in the 2024 Jefferies Global Healthcare Conference. The event will feature a fireside chat with CEO Sergio Traversa and CFO Maged Shenouda on June 6, 2024, at 7:30am ET in New York, NY. The management team will also host one-on-one investor meetings during the conference. The fireside chat will be webcast live and accessible through the Investors section of Relmada's website, with an archived replay available for 30 days post-event.
Relmada Therapeutics, Inc. provided a corporate update and reported first-quarter 2024 financial results, highlighting advancements in their Phase 3 programs for major depressive disorder treatment. They plan to commence a Phase 1 trial for modified-release psilocybin in obese patients. Financially, research and development expenses decreased, general and administrative expenses lowered, and net cash used in operating activities declined. The net loss was reduced, with the company holding approximately $83.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024.
Relmada Therapeutics, Inc. (RLMD) will release its first quarter financial results on May 8, 2024, followed by a conference call and webcast discussing the results and corporate updates.
FAQ
What is the current stock price of Relmada Therapeutics (RLMD)?
What is the market cap of Relmada Therapeutics (RLMD)?
